# GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

> **NCT04060316** · PHASE2 · UNKNOWN · sponsor: **GeneOne Life Science, Inc.** · enrollment: 99 (estimated)

## Conditions studied

- Sinusitis Chronic

## Interventions

- **DRUG:** GLS-1200
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04060316
- **Lead sponsor:** GeneOne Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2023-12
- **Final completion:** 2024-09
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060316, "GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04060316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*